Trial Profile

A phase 1/2 study of PORT-2 in non-small cell lung cancer (NSCLC) and refractory melanoma in the US and European Union

Status: Suspended

Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Threitolceramide 6 (Primary)
Indications Malignant melanoma; Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms IMPORT-201
Sponsors Portage Biotech

Most Recent Events

04 Jan 2024 Status changed from recruiting to suspended, according to Portage Biotech media release.
04 Jan 2024 According to a Portage Biotech media release, after a review of company's funding requirements, the Board of Directors has made a decision to pause further drug development in the PORT-2 iNKT program.
05 Jun 2023 Status changed from planning to recruiting according to a Portage Biotech media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com